Detect & Analyze Dengue Virus Sequences with Bhedi
India accounts for over 40% of the global burden of dengue.
In 2022, there were over 4.8 million reported cases of dengue in India.
Dengue is most prevalent in India during the monsoon season, from June to September.
Dengue is a major public health problem in India and globally, and it is important to raise awareness of the disease and its prevention.
Learn about Objectives laid down by NCVBDC and trends from DENGUE/DHF Situation in India
Computational analysis shows how dengue virus evolved in India
A multi-institutional study on dengue led by researchers at the Indian Institute of Science (IISc) shows how the virus causing the disease has evolved dramatically over the last few decades in the Indian subcontinent.
Checkout A joint publication of the World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases (TDR)
European Centre for Disease Prevention and Control (ECDC): Link to ECDC Dengue Guidelines
In 2022, there were over 4.8 million reported cases of dengue in India.
Dengue is most prevalent in India during the monsoon season, from June to September.
Children under the age of 15 are the most affected by dengue.
The fatality rate for dengue in India is around 1%, but it can be much higher in children and people with underlying medical conditions.
Dengue is a major public health problem in India, and it is important to raise awareness of the disease and its prevention.
India accounts for over 40% of the global burden of dengue.
In 2022, there were over 4.8 million reported cases of dengue in India.
Dengue is most prevalent in India during the monsoon season, from June to September.
Children under the age of 15 are the most affected by dengue.
India observes National Dengue Day on May 16 every year.
It is an initiative by the Ministry of Health and Family Welfare to educate the public about dengue prevention and control measures
Indian Immunologicals targets dengue vaccine launch by January 2026
Moving closer to being able to develop the country’s first vaccine against dengue, drug-makers Serum Institute of India and Panacea Biotec have applied to the Indian Council of Medical Research’s (ICMR) call for ‘Expression of Interest’ for collaborative Phase-III clinical trials for indigenous manufacturers.
The National Vector Borne Diseases Control Programme (NVBDCP) is an umbrella programme for prevention and control of vector borne diseases viz. Malaria, Japanese Encephalitis (JE), Dengue, Chikungunya, Kala-azar and Lymphatic Filariasis.
The fatality rate for dengue in India is around 1%, but it can be much higher in children and people with underlying medical conditions.
Dengue is a major public health problem in India, and it is important to raise awareness of the disease and its prevention.
CSIR IGIB
AcSIR
RF
Jitendra Lab
Join Us
